A Phase 2 interventional study of Megestrol Acetate 160 MG Oral Tablet and Medroxyprogesterone Acetate 500 MG in Endometrial Neoplasm Malignant Stage I, sponsored by Fudan University. Active, not recruiting at 1 site in China. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-23.
Sponsored by Fudan University · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing letrozole in Endometrial Neoplasms — 5 open to participants now, 9 under way, 3 of them phase 3. Letrozole · Endometrial Neoplasms.
Among the 17 studies testing letrozole in Endometrial Neoplasms, this one is the 3rd largest by planned enrollment, is one of 4 that started in 2022, is one of 12 in phase 2, and was the 12th registered.
1,429 studies on the registry are indexed under Endometrial Neoplasms; 470 are open to participants now.
Browse Endometrial Neoplasms studies →5 of the 17 studies testing letrozole in Endometrial Neoplasms are open now, in 2 countries. Recruiting first, the newest first:
Fudan University · Sites in China
Ages 18–45 · Women only
Dana-Farber Cancer Institute · Sites in United States
Ages 18+
Xiaojun Chen · Sites in China
Ages 18–45 · Women only
Xiaojun Chen · Sites in China
Ages 18–45 · Women only
Dana-Farber Cancer Institute · Sites in United States
Ages 18+ · Women only
By country, each count listing its studies:
Letrozole: first FDA approval 1997 (FEMARA). What it is approved for, and how studies give it, is on its page →
Of the 356 Endometrial Neoplasms studies recruiting now, 266 (75%) set no upper age limit and 54 (15%) stop at 75 or younger; 26 take children under 18; 23 take healthy volunteers.
This study: 18 Years to 45 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 16 · Phase 3 4
First in 2000; this study’s year is marked. 4 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 104 is above the median of 71 across 1,029 interventional studies indexed under Endometrial Neoplasms.
Median enrollment 53 across the 17 interventional studies. Of the 8 that completed or were terminated, 3 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 17 have an industry lead sponsor. The 10 most frequent:
Fudan University is the lead sponsor of 1,319 studies on the registry; 647 are open to participants now.
Fudan University has 8 studies filed under Endometrial Neoplasms — fewer than ten, so there is no comparison to draw.
3 of the studies testing letrozole in Endometrial Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04393285Gynecologic Oncology GroupAbemaciclib and Letrozole to Treat Endometrial Cancer | 2026-12-01 |
| NCT05247268Fudan UniversityGonadotropin-releasing Hormone Agonist (GnRHa) Plus Letrozole In Young Women With Early Endometrial Cancer | 2027-03-10 |
| NCT06366347Dana-Farber Cancer InstituteALPINE: Maintenance Letrozole/Abemaciclib | 2027-09-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 17 studies testing letrozole in Endometrial Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To see if Gonadotropin-releasing hormone analogue (GnRHa) combined with aromatase inhibitors (AIs) will achieve better complete response rate than megestrol acetate or medroxyprogesterone acetate (MA/MPA) alone as fertility-sparing treatment for patients with early endometrial carcinoma.
This will be a multicenter randomized controlled study to evaluate the treatment effects and adverse events of GnRHa plus AIs compared with MA/MPA in primary EEC patients.In this study, young patients (18-45 years) diagnosed as EEC for the first time seeking for fertility preserving treatment at the Obstetrics and Gynecology Hospital of Fudan University were screened. Patients were randomly assigned (1:1) to GnRHa+letrozole group (triprorelin acetate, intramuscular injection of 3.75mg was given 4 weeks apart and the maximum use are 6 courses. letrozole, 2.5mg oral daily and no more than 24 weeks) or MA/MPA group (160 mg oral MA daily or 500 mg oral MPA daily).
Hysteroscopy will be performed every 3 months during treatment to evaluate the treatment effects. For patients with EEC, complete response (CR) is defined as the reversion of endometrial carcinoma to proliferative or secretory endometrium; partial response (PR) is defined as regression to simple or complex hyperplasia with or without atypia; Stable disease (SD) is defined as the persistence of the disease; and progressive disease (PD) is defined as the progression of endometrial lesions. Continuous therapies will be needed in PR, SD or PD.The primary endpoint was cumulative complete response (CR) rate at 16 weeks of treatment. The secondary endpoints were cumulative CR rate at 28weeks of treatment, adverse events, recurrent rate, pregnancy rate, effects on ovarian function and quality of life of patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will be stratified into BMI≥28kg/m2 group and BMI\<28kg/m2 group. Patients in BMI≥28kg/m2 or BMI\<28kg/m2 group will be randomly assigned (1:1) to GnRHa+letrozole group or MA/MPA group. Patients who will be assigned to GnRHa+letrozole group will receive triprorelin acetate (intramuscular injection of 3.75mg was given 4 weeks apart and the maximum use are 6 courses) plus letrozole (2.5mg oral daily and no more than 24 weeks). Then every 3 months, an hysteroscope will be used to evaluate the endometrial condition, and the findings will be recorded.
Drug: Triprorelin Acetate · Drug: Letrozole 2.5mg
Patients will be stratified into BMI≥28kg/m2 group and BMI\<28kg/m2 group. Patients in BMI≥28kg/m2 or BMI\<28kg/m2 group were randomly assigned (1:1) to GnRHa+letrozole group or MA/MPA group.Patients assigned to MA/MPA group will receive MA/MPA (160 mg oral MA daily or 500 mg oral MPA daily).Then every 3 months, an hysteroscopy will be used to evaluate the endometrial condition, and the findings will be recorded.
Drug: Megestrol Acetate 160 MG Oral Tablet · Drug: Medroxyprogesterone Acetate 500 MG
At a dosage of 160 mg/day
Also known as: Megestrol Acetate
At a dosage of 500 mg/day
Also known as: Medroxyprogesterone Acetate
Intramuscular injection of 3.75mg was given 4 weeks apart and the maximum use are 6 courses
At a dosage of 2.5mg/day and no more than 24 weeks
Also known as: Letrozole
Complete response rates within 16 weeks of treatment
The cumulative 16-week CR rates will be calculated in two groups
Time frame: From date of treatment initiation until the date of CR, assessed up to 16 weeks.
Complete response rates within 28 weeks of treatment
The cumulative 28-week CR rates will be calculated in two groups
Time frame: From date of treatment initiation until the date of CR, assessed up to 28 weeks.
Time to achieve complete response
The median CR time will be calculated in two groups
Time frame: From date of treatment initiation until the date of CR or date of hysterectomy,From date of randomization until the date of CR, assessed up to 2 years
Adverse events
Adverse events related with Medroxyprogesterone Acetate, Megestrol Acetate, Triprorelin Acetate and Letrozole. Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 will be recorded, as well as incidence of adverse events.
Time frame: From date of treatment initiation until the date of CR, assessed up to 2 years
Quality of life during the treatment accessed by WHOQOL-BREF
Quality of life will be assessed at baseline, 4 weeks and every 12-16 weeks of treatment, using WHOQOL-BREF scale including assessment on pain, energy,sleep,mobil,activity,medication,work,positive feeling,think,esteem,body,negtivity,spirit,relationship,support,sex,safety,home,finance,service,information, environment,leisure,transport
Time frame: From date of randomization until 12 weeks after treatment is over.
Relapse rates
All enrolled patients will be followed up for 2 years. During the following-up period, if patients recur after complete response, they will be counted and the number of recurrence will be divided by number of patients followed up, then we can get the relapse rates. Comparison will be performed between two groups.
Time frame: up to 2 years after the treatment for each patient
Change of AMH (anti-mullerian hormone ) serum level
AMH (anti-mullerian hormone ) will be assessed at baseline and every 12-16 weeks.
Time frame: From date of randomization until 24 weeks after treatment is over.
The rates of fertility outcomes
The percentage of pregnancy and live-birth will be counted.
Time frame: up to 2 years after the treatment for each patient
Plan to share: Yes — Data will be shared after this research being published,without patients personal information.
Supporting information: Study protocol
Time frame: Data will be avaliable since this research being published
Access criteria: Institutes or researchers who require the data should contact the principle investigator Prof.Xiaojun Chen via email that after this study being published.
Started Mar 2022 (actual). Primary completion is estimated for Mar 2027, 59 months after the start.
Of 109 non-industry phase 2 interventional studies under Endometrial Neoplasms, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 115. This study's planned 59 months is close to that.
Counting every sponsor, half of 141 studies reached it within 55 months; a quarter within 37 and three quarters within 115.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Letrozole